Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dropbox Inc (DBX) vs Mesoblast Limited (MESO) Price & Performance

Dropbox IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Dropbox Inc vs Mesoblast Limited — how do they compare? Dropbox Inc trades at $29.53 (market cap $6.99B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Dropbox Inc is far larger — about 3.3× Mesoblast Limited's market cap. Which is the better fit depends on your goals.

DBXMESO
Market Cap
$6.99B$2.12B
Sector
TechnologyTechnology
52-Week High
$32.17$20.96
52-Week Low
$22.06$10.96
Enterprise Value
$9.71B$2.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dropbox Inc

Dropbox (DBX) trades at $29.58, up 1.34% on the day, near the analyst consensus price target of $30. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate potential overbought conditions. Fundamentally, the company maintains robust profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent news highlights a new $900 million stock repurchase program and a CEO transition plan announced in May 2026.

The outlook is balanced with solid fundamentals and shareholder returns offset by high debt levels and mixed analyst sentiment. Investment appeal lies in consistent earnings beats and capital return initiatives, but risks include elevated leverage and competitive pressures in cloud storage. The stock presents a moderate opportunity with cautious optimism warranted given its valuation near target prices.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dropbox Inc

Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.

Read more on DBX

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO